retatrutide triple agonist glp-1 gip glucagon phase 2 nejm 2023 Retatrutide, a (GLP1, GIP, glucagon), just released trial results demonstrating 25% weight loss in half of people with #obesity. This amount of weight loss has not been accomplished ๐ง๐ต๐ฒ ๐๐ณ๐ณ๐ฒ๐ฐ๐ ๐ผ๐ณ ๐๐๐ฃ-๐ญ ๐ฅ๐ฒ๐ฐ๐ฒ๐ฝ๐๐ผ๐ฟ
Pay in 4 interest-free payments of $7.00 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours ยท Estimated delivery Oct 2 - Oct 7







:max_bytes(150000):strip_icc()/Health-GettyImages-1675158771-70640c9fdf1b41078975cfc3fd538a6b.jpg)




















